Ardelyx, Inc.

ARDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012
Operating Activities
Net Income $-64.3M $-112.4M $-29.6M $-3.2M $-6.6M $-9.8M
Depreciation & Amortization $2.6M $1.3M $800.0K $300.0K $600.0K $675.0K
Depreciation $2.6M $1.3M $829.0K $302.0K $592.0K —
Amortization — — — — — —
Stock-Based Compensation $9.6M $5.3M $2.6M $1.7M $352.0K $473.0K
Net Cash from Operating Activities $-65.2M $-92.5M $-71.8M $13.4M $1.8M $22.0M
Investing Activities
Capital Expenditures $2.4M $4.9M $3.5M $1.9M $278.0K $128.0K
Business Acquisitions — — — — — —
Net Cash from Investing Activities $65.3M $-131.1M $-3.5M — — —
Financing Activities
Dividends Paid — — — — — —
Stock Repurchases — — — $2.0K $2.0K $20.0K
Net Cash from Financing Activities $685.0K $191.2M $75.0M — — —
Net Change in Cash $785.0K $-32.4M $-282.0K $72.9M $1.5M $22.1M
Free Cash Flow $-67.5M $-97.4M $-75.3M $11.5M $1.5M $21.9M
← Newer Page 2 of 2 Older →